Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment

Abstract Background The combination of CTLA-4 and PD-L1 inhibitors has a manageable adverse effect profile, although rare immune-related adverse events (irAE) can occur. Case presentation We describe an autoimmune polymyositis following a partial response to combination tremelimumab and durvalumab f...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Sooraj John, Scott J. Antonia, Trevor A. Rose, Robert P. Seifert, Barbara A. Centeno, Aaron S. Wagner, Ben C. Creelan
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMJ Publishing Group 2017-07-01
Edice:	Journal for ImmunoTherapy of Cancer
Témata:	Immune-related adverse event Non-small cell lung cancer Programmed death protein 1 Programmed death-ligand 1 Cytotoxic T-lymphocyte-associated-protein 4 Immune checkpoint inhibitor
On-line přístup:	http://link.springer.com/article/10.1186/s40425-017-0258-x
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!